TheraMAB Overview

  • Founded
  • 2009
  • Status
  • Out of Business
  • Employees
  • 4
  • Latest Deal Type
  • Out of Business

TheraMAB General Information


Developer of an immunotherapeutic monoclonal drug designed to treat autoimmune diseases. The company's drug is used for the treatment of major diseases in the field of oncologyl, enabling physicians to begin treatment quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Stolovy per. 6
  • Building 2
  • Moscow, 121069
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TheraMAB Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Sep-2018 000.00 Completed Out of Business
2. Early Stage VC 01-Mar-2012 000.00 000.00 Completed Clinical Trials - Phase 1
1. Grant 16-Feb-2012 $5M Completed Generating Revenue
To view TheraMAB’s complete valuation and funding history, request access »

TheraMAB Executive Team (2)

Name Title Board Seat Contact Info
Dmitry Tyrsin Ph.D Chief Executive Officer
Alexey Matskevich Ph.D Chief Researcher
To view TheraMAB’s complete executive team members history, request access »

TheraMAB Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial